Earnings Call Summary | Kiniksa Pharmaceuticals(KNSA.US) Q1 2024 Earnings Conference
Earnings Call Summary | Kiniksa Pharmaceuticals(KNSA.US) Q1 2024 Earnings Conference
The following is a summary of the Kiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Call Transcript:
以下是基尼克薩製藥有限公司（KNSA）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Kiniksa Pharmaceuticals reported strong Q1 2024 results with an 85% year-over-year increase in ARCALYST net product revenue to $78.9 million.
The company has updated their revenue guidance for 2024 from $360 million-$380 million to $370 million-$390 million.
The net loss for Q1 2024 was $17.7 million, compared to $12.3 million in the same period of the previous year.
Kiniksa Pharmicals公佈了強勁的2024年第一季度業績，ARCALYST的淨產品收入同比增長85％，達到7,890萬美元。
該公司已將2024年的收入指引從3.6億美元至3.8億美元更新至3.7億美元至3.9億美元。
2024年第一季度的淨虧損爲1,770萬美元，而去年同期爲1,230萬美元。
Business Progress:
業務進展：
Kiniksa plans to initiate a Phase 2b trial with Abiprubart in Sjögren's Disease and is intensifying its R&D efforts while monitoring the competitive landscape in CD40-CD154 antagonist class.
The company aims to remain cash flow positive on an annual basis. Kiniksa intends to increase awareness of ARCALYST, and they are exploring further business development opportunities and potential strategic expansions.
Kiniksa計劃與Abiprubart一起啓動一項針對舍格倫氏病的2b期試驗，並正在加強研發工作，同時監測 CD40-CD154 拮抗劑類別的競爭格局。
該公司的目標是每年保持正現金流。Kiniksa打算提高對ARCALYST的認識，他們正在探索進一步的業務發展機會和潛在的戰略擴張。
More details: Kiniksa Pharmaceuticals IR
更多詳情： Kiniksa 製藥公司 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。